OPKO Health (OPK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual Meeting scheduled for June 18, 2026, to be held virtually, with voting on key proposals including director elections, equity incentive plan, executive compensation, and auditor ratification.
Record date for voting is April 20, 2026, with 755,092,256 shares outstanding and each share entitled to one vote.
Proxy materials, including the 2025 Annual Report, were distributed starting April 30, 2026.
Voting matters and shareholder proposals
Election of eleven directors for terms expiring at the 2027 annual meeting.
Approval of the 2026 Equity Incentive Plan to replace the 2016 plan, authorizing 30 million new shares for awards.
Advisory vote on executive compensation (Say on Pay).
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Other business as may properly come before the meeting.
Board of directors and corporate governance
Board consists of 11 members, majority independent per NASDAQ standards.
Lead independent director identified; all standing committees chaired by independent directors.
Board met six times in 2025; high attendance by directors.
Committees include Audit, Compensation, Corporate Governance and Nominating, Independent Investment, and Succession.
Director selection emphasizes diverse backgrounds and experience; no formal diversity policy but diversity considered.
Latest events from OPKO Health
- Q4 revenue dropped post-divestiture, but R&D and pharma growth support a strong 2026 outlook.OPK
Q4 20258 Jul 2026 - Q1 2025 saw lower losses, strong cash, asset sales, and a $225M oncology deal with LabCorp.OPK
Q1 20258 Jul 2026 - Q3 2025 saw a major asset sale, higher operating income, and strong cash reserves.OPK
Q3 20258 Jul 2026 - All proposals passed; clinical pipeline and cash flow strong; $98M buyback authorization remains.OPK
AGM 202618 Jun 2026 - Multiple clinical milestones expected in 2024-2025, including key data from MDX-2001 and Merck EBV vaccine.OPK
Jefferies Global Healthcare Conference 20263 Jun 2026 - Approval of the 2026 Equity Incentive Plan is sought to maintain equity-based compensation.OPK
Proxy filing15 May 2026 - Advancing a broad clinical pipeline and global partnerships, supported by strong financials.OPK
Corporate presentation13 May 2026 - Key votes include board elections, equity plan approval, say-on-pay, and auditor ratification.OPK
Proxy filing30 Apr 2026 - Q1 2026 revenue fell, but losses narrowed and liquidity and clinical progress remained strong.OPK
Q1 202628 Apr 2026